All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized with synovial joint destructions and extra-articular manifestations. The etiology of RA is still unknown, but environmental and genetic factors were thought to be involved in the pathogenesis of RA \[[@pone.0204459.ref001],[@pone.0204459.ref002],[@pone.0204459.ref003]\]. Human leukocyte antigen (HLA) is the strongest genetic factor in RA and it was confirmed in genome wide association studies based on single nucleotide polymorphisms \[[@pone.0204459.ref004]\]. *DRB1* was believed to be the most important locus in *HLA* for the susceptibility of RA; some *DRB1* alleles were associated with the susceptibility of RA and have common motifs of amino acid residues at position 70--74 (QKRAA, RRRAA, or QRRAA) in DRβ chain \[[@pone.0204459.ref005]\]. These were designated as shared epitope (SE) alleles \[[@pone.0204459.ref006]\]. *DRB1\*04*:*01* was mainly associated with RA in European populations \[[@pone.0204459.ref005]\] and *DRB1\*04*:*05* in Asian \[[@pone.0204459.ref007]\]. Although both of *DRB1\*04*:*01* and *DRB1\*04*:*05* are SE alleles, these differences could be explained by the different frequencies of these susceptibility alleles for RA in different ethnic groups. The production of anti-citrullinated peptide antibodies (ACPA) is specifically associated with RA. ACPA-positive RA \[ACPA(+)RA\] is strongly associated with SE alleles, but ACPA-negative RA \[ACPA(-)RA\] is weakly \[[@pone.0204459.ref007],[@pone.0204459.ref008],[@pone.0204459.ref009]\].

Some reports also suggested that *B*, *DQB1*, or *DPB1* would be involved in the pathogenesis of RA \[[@pone.0204459.ref010],[@pone.0204459.ref011],[@pone.0204459.ref012],[@pone.0204459.ref013],[@pone.0204459.ref014],[@pone.0204459.ref015],[@pone.0204459.ref016],[@pone.0204459.ref017],[@pone.0204459.ref018],[@pone.0204459.ref019],[@pone.0204459.ref020]\]. Since *HLA* region is in strong linkage disequilibrium, it is important to eliminate the effects of *DRB1* to elucidate the role of other loci in *HLA*. The independent associations of amino acid residues in *B* and *DPB1* loci were recently reported \[[@pone.0204459.ref021],[@pone.0204459.ref022],[@pone.0204459.ref023]\]. However, few studies reported on the independent associations of *DPB1* alleles for RA susceptibility. Since *DRB1* is the strongest genetic risk factor for ACPA(+)RA, we investigated the independent association of *DPB1* alleles from *DRB1* in Japanese ACPA(+)RA.

Materials and methods {#sec006}
=====================

Patients {#sec007}
--------

One thousand six hundred sixty seven Japanese RA patients were recruited at Hyogo College of Medicine, Jichi Medical University, Miyakonojo Medical Center, Nagasaki Medical Center, Nagoya Medical Center, Niigata Rheumatic Center, Sagamihara National Hospital, Tochigi Rheumatology Clinic, Tokyo Metropolitan Tama Medical Center, or Yokohama Minami Kyosai Hospital. RA patients fulfilled the 1987 American College of Rheumatology criteria for RA \[[@pone.0204459.ref024]\] or the 2010 Rheumatoid Arthritis Classification Criteria \[[@pone.0204459.ref025]\]. Four hundred thirteen Japanese healthy controls (mean age ± SD, 39.3 ± 11.0 years, vs. ACPA(+)RA: *P* = 6.50X10^-130^, vs. ACPA(-)RA, *P* = 5.51X10^-71^, 61 male \[14.8%\], vs. ACPA(+)RA: *P* = 0.0792, vs. ACPA(-)RA, *P* = 0.2195) were recruited at Kanazawa University, Sagamihara National Hospital, and Teikyo University \[[@pone.0204459.ref026]\] or by the Pharma SNP Consortium (Tokyo, Japan) \[[@pone.0204459.ref027],[@pone.0204459.ref028]\]. Rheumatoid factor and ACPA were measured by N-latex RF kit (Siemens Healthcare Diagnostics, München, Germany) or Mesacup-2 test CCP (Medical & Biological Laboratories, Nagoya, Japan), respectively. This study was reviewed and approved by Hyogo College of Medicine Research Ethics Committee, Jichi Medical University Research Ethics Committee, Miyakonojo Medical Center Research Ethics Committee, Nagasaki Medical Center Research Ethics Committee, Nagoya Medical Center Research Ethics Committee, Niigata Rheumatic Center Research Ethics Committee, Sagamihara National Hospital Research Ethics Committee, Tokyo Metropolitan Tama Medical Center Research Ethics Committee, Yokohama Minami Kyosai Hospital Research Ethics Committee, and University of Tsukuba Research Ethics Committee. Written informed consent was obtained from all study participants. This study was conducted in accordance with the principles expressed in the Declaration of Helsinki.

Genotyping of *DRB1* and *DPB1* {#sec008}
-------------------------------

Genotyping of *DRB1* and *DPB1* was performed by polymerase chain reaction with reverse sequence-specific oligonucleotide probes (WAKFlow HLA typing kit, Wakunaga Pharmaceutical Co., Ltd., Akitakata, Japan) and Bio-Plex 200 (Bio-Rad, Hercules, CA). SE alleles contain *DRB1\*01*:*01*, *DRB1\*04*:*01*, *DRB1\*04*:*05*, *DRB1\*04*:*10*, *DRB1\*10*:*01*, and *DRB1\*14*:*06* \[[@pone.0204459.ref005]\]. Genotyping results for some of the RA patients and the healthy controls were previously reported \[[@pone.0204459.ref007],[@pone.0204459.ref026],[@pone.0204459.ref029],[@pone.0204459.ref030],[@pone.0204459.ref031],[@pone.0204459.ref032]\].

Statistical analysis {#sec009}
--------------------

Clinical features of the RA patients were analyzed by Fisher's exact test using 2X2 contingency tables or Student's t-test. Unconditioned logistic regression analysis under the additive model was performed to analyze nominal associations of *HLA* alleles with the susceptibility of RA. On the other hand, conditioned logistic regression analysis was used to investigate the independent contribution of each *DPB1* allele from *DRB1* to the susceptibility of RA. *P*~adjusted~ and OR~adjusted~ were calculated for *DPB1* alleles, when conditioned on *DRB1*. Alleles detected in both case and control groups were tested. The two-locus analysis was also conducted by logistic regression analysis under the additive model to identify the primary role of associated *DRB1* or *DPB1* alleles. Haplotype frequencies of *DRB1-DPB1* were estimated with expectation-maximization algorithm with SNPAlyze ver.8.0.4 Pro (Dynacom, Chiba, Japan) and Permutation *P* values were established by 100000 permutations. Logistic regression analysis under the additive model was also performed to analyze associations of amino acid residues; conditional logistic regression analysis was used to investigate the independent contribution of each DPβ chain amino acid residue from DRβ chain amino acid residues to the susceptibility of RA. *P*~adjusted~ values were calculated for amino acid residues in the DPβ chains, when conditioned on DRβ chain amino acid residues. Multiple comparisons were adjusted by Bonferroni method; corrected *P* (*Pc*) values were derived from multiplying the *P* values by the number of alleles or amino acid residues tested.

Results {#sec010}
=======

Clinical manifestations of RA patients {#sec011}
--------------------------------------

Characteristics of RA patients are shown in [Table 1](#pone.0204459.t001){ref-type="table"}. Steinbrocker stage and class \[[@pone.0204459.ref033]\] were higher in ACPA(+)RA than ACPA(-)RA. The rheumatoid factor positivity rate was also higher.

10.1371/journal.pone.0204459.t001

###### Characteristics of RA patients.

![](pone.0204459.t001){#pone.0204459.t001g}

                                         ACPA(+)RA     ACPA(-)RA     *P*
  -------------------------------------- ------------- ------------- ---------------------------------------------
  Number                                 1436          231           
  Mean age, years (SD)                   62.8 (12.3)   61.8 (12.5)   [\*](#t001fn002){ref-type="table-fn"}0.2991
  Male, n (%)                            267 (18.7)    43 (18.7)     1.0000
  Age at onset (SD)                      49.8 (14.3)   51.9 (16.0)   [\*](#t001fn002){ref-type="table-fn"}0.0850
  Steinbrocker stage III and IV, n (%)   629 (48.6)    61 (31.8)     1.26X10^-5^
  Steinbrocker class 3 and 4, n (%)      195 (15.1)    15 (7.9)      0.0072
  Rheumatoid factor positive, n (%)      1192 (88.8)   79 (37.4)     1.86X10^-56^

RA: rheumatoid arthritis, ACPA: anti-citrullinated peptide antibody, ACPA(+)RA: ACPA positive RA, ACPA(-)RA: ACPA negative RA. Association was tested between ACPA(+)RA and ACPA(-)RA by Fisher's exact test using 2X2 contingency tables or Student's t-test.

\*Student's t-test was employed.

Association of *DPB1* with ACPA(+)RA {#sec012}
------------------------------------

Association of *DRB1* with ACPA(+)RA was confirmed ([S1 Table](#pone.0204459.s002){ref-type="supplementary-material"}), as reported in the previous study \[[@pone.0204459.ref007]\]; *DRB1\*04*:*05* and *\*04*:*01* were associated with the susceptibility of ACPA(+)RA and *DRB1\*04*:*06*, *\*08*:*02*, *\*08*:*03*, *\*13*:*02*, and *\*14*:*03* were protectively associated. Next, it was analyzed whether *DPB1* was also associated with ACPA(+)RA ([Table 2](#pone.0204459.t002){ref-type="table"}). In unconditioned analysis, *DPB1\*04*:*02* was nominally associated with the susceptibility of ACPA(+)RA (*P* = 0.0021, *P*c = 0.0275, odds ratio \[OR\] 1.52, 95% confidence interval \[CI\] 1.16--1.99, [Table 2](#pone.0204459.t002){ref-type="table"}, left column). Since *DRB1* and *DPB1* are in strong linkage disequilibrium, nominal associations of *DPB1* alleles were influences by the associations of *DRB1* alleles with ACPA(+)RA. In order to clarify whether each *DPB1* allele was independently associated with ACPA(+)RA, conditional logistic regression analysis was performed ([Table 2](#pone.0204459.t002){ref-type="table"}, right column). The significant association of *DPB1\*02*:*01* with the susceptibility of ACPA(+)RA was observed, when conditioned on *DRB1* (*P*~adjusted~ = 0.0003, *P*c~adjusted~ = 0.0040, OR~adjusted~ 1.47, 95%CI 1.19--1.81, [Table 2](#pone.0204459.t002){ref-type="table"}, right column). *DPB1\*05*:*01* was tended to be associated with the protection against ACPA(+)RA, when conditioned on *DRB1* (*P*~adjusted~ = 0.0091, *P*c~adjusted~ = 0.1184, OR~adjusted~ 0.78, 95%CI 0.65--0.94, [Table 2](#pone.0204459.t002){ref-type="table"}, right column). When conditioned on *DRB1*, *DPB1\*04*:*02* was not associated with the susceptibility of ACPA(+)RA, suggesting the influence of *DRB1* on the nominal association of *DPB1\*04*:*02*. Thus, *DPB1\*02*:*01* was independently associated with the susceptibility of ACPA(+)RA.

10.1371/journal.pone.0204459.t002

###### Conditional logistic regression analysis of *DPB1* alleles in ACPA(+) RA and controls.
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                    Uncoditioned   Conditioned on *DRB1*                                                                          
  ----------------- -------------- ----------------------- ------ -------------- -------- -------- ------ -------------- -------- --------
  *DPB1\*02*:*01*   781 (27.2)     198 (24.0)              1.19   (0.99--1.42)   0.0644   0.8371   1.47   (1.19--1.81)   0.0003   0.0040
  *DPB1\*02*:*02*   119 (4.1)      34 (4.1)                1.01   (0.68--1.49)   0.9723   NS       1.09   (0.69--1.72)   0.6998   NS
  *DPB1\*03*:*01*   113 (3.9)      36 (4.4)                0.91   (0.62--1.33)   0.6150   NS       0.80   (0.52--1.24)   0.3141   NS
  *DPB1\*04*:*01*   98 (3.4)       44 (5.3)                0.64   (0.45--0.92)   0.0147   0.1909   1.00   (0.58--1.72)   0.9912   NS
  *DPB1\*04*:*02*   351 (12.2)     69 (8.4)                1.52   (1.16--1.99)   0.0021   0.0275   1.12   (0.79--1.58)   0.5362   NS
  *DPB1\*05*:*01*   1054 (36.7)    319 (38.6)              0.92   (0.78--1.08)   0.3114   NS       0.78   (0.65--0.94)   0.0091   0.1184
  *DPB1\*06*:*01*   15 (0.5)       3 (0.4)                 1.44   (0.42--5.01)   0.5638   NS       2.15   (0.56--8.22)   0.2640   NS
  *DPB1\*09*:*01*   218 (7.6)      87 (10.5)               0.70   (0.54--0.91)   0.0072   0.0930   0.67   (0.40--1.10)   0.1132   NS
  *DPB1\*13*:*01*   36 (1.3)       19 (2.3)                0.53   (0.30--0.94)   0.0297   0.3862   0.57   (0.31--1.06)   0.0782   NS
  *DPB1\*14*:*01*   44 (1.5)       8 (1.0)                 1.60   (0.75--3.43)   0.2262   NS       1.06   (0.45--2.48)   0.9019   NS
  *DPB1\*17*:*01*   6 (0.2)        3 (0.4)                 0.57   (0.14--2.30)   0.4330   NS       0.49   (0.05--5.05)   0.5478   NS
  *DPB1\*19*:*01*   13 (0.5)       2 (0.2)                 1.88   (0.42--8.35)   0.4082   NS       1.08   (0.23--5.08)   0.9216   NS
  *DPB1\*41*:*01*   7 (0.2)        2 (0.2)                 1.01   (0.21--4.86)   0.9934   NS       0.87   (0.14--5.48)   0.8826   NS

RA: rheumatoid arthritis, ACPA: anti-citrullinated peptide antibody, ACPA(+)RA: ACPA positive RA, OR: odds ratio, CI: confidence interval, *P*c: corrected *P* value, NS: not significant. Allele frequencies are shown in parenthesis (%).The association of each *DPB1* allele with ACPA(+)RA was analyzed by logistic regression analysis. The left column indicates the results from unconditioned analyses. The right column indicates the results from analyses conditioned on *DRB1*. *P*~adjusted~ and OR~adjusted~ were calculated by conditional logistic regression analysis under the additive model. Corrected *P* (*P*c) values were calculated by multiplying the *P* value by the number of alleles tested.

In order to reveal whether each *DRB1* allele influenced on the association of *DPB1\*02*:*01* with the susceptibility of ACPA(+)RA, conditional logistic regression analysis was conducted ([Table 3](#pone.0204459.t003){ref-type="table"}). When conditioned on *DRB1\*04*:*05*, the significant association of *DPB1\*02*:*01* with the susceptibility of ACPA(+)RA was observed (*P*~adjusted~ = 0.0073, OR~adjusted~ 1.29, 95%CI 1.07--1.56, [Table 3](#pone.0204459.t003){ref-type="table"}). Because *DRB1\*04*:*05* is the strongest risk factor for RA in Asian \[[@pone.0204459.ref007]\], the influence of *DRB1\*04*:*05* on the nominal association of *DPB1\*02*:*01* would be strongest. However, the stronger association of *DPB1\*02*:*01* with the susceptibility of ACPA(+)RA was observed, when conditioned on SE alleles (*P*~adjusted~ = 0.0016, OR~adjusted~ 1.37, 95%CI 1.13--1.66, [Table 3](#pone.0204459.t003){ref-type="table"}) or *DRB1* (*P*~adjusted~ = 0.0003, OR~adjusted~ 1.47, 95%CI 1.19--1.81, [Table 3](#pone.0204459.t003){ref-type="table"}). These data suggested that many *DRB1* alleles including *DRB1\*04*:*05* had influenced on the nominal association of *DPB1\*02*:*01* with the susceptibility of ACPA(+)RA.

10.1371/journal.pone.0204459.t003

###### Conditional logistic regression analysis of *DPB1\*02*:*01* between ACPA(+) RA and controls.
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  ----------------------------------- -------------- -------------- ---------------
  Uncoditioned                                                      
                                      OR             95%CI          *P*
                                      1.19           (0.99--1.42)   0.0644
  Conditioned on each *DRB1* allele                                 
                                      OR~adjusted~   95%CI          *P*~adjusted~
  *DRB1\*01*:*01*                     1.22           (1.02--1.47)   0.0307
  *DRB1\*04*:*01*                     1.17           (0.97--1.40)   0.0934
  *DRB1\*04*:*03*                     1.20           (1.00--1.43)   0.0507
  *DRB1\*04*:*05*                     1.29           (1.07--1.56)   0.0073
  *DRB1\*04*:*06*                     1.25           (1.04--1.51)   0.0165
  *DRB1\*04*:*07*                     1.19           (0.99--1.42)   0.0590
  *DRB1\*04*:*10*                     1.19           (0.99--1.42)   0.0596
  *DRB1\*07*:*01*                     1.18           (0.99--1.42)   0.0655
  *DRB1\*08*:*02*                     1.22           (1.01--1.46)   0.0359
  *DRB1\*08*:*03*                     1.20           (1.00--1.43)   0.0520
  *DRB1\*09*:*01*                     1.18           (0.98--1.41)   0.0740
  *DRB1\*10*:*01*                     1.17           (0.98--1.40)   0.0844
  *DRB1\*11*:*01*                     1.19           (0.99--1.42)   0.0596
  *DRB1\*12*:*01*                     1.18           (0.98--1.41)   0.0776
  *DRB1\*12*:*02*                     1.19           (0.99--1.42)   0.0644
  *DRB1\*13*:*01*                     1.20           (1.00--1.44)   0.0454
  *DRB1\*13*:*02*                     1.16           (0.97--1.39)   0.1052
  *DRB1\*14*:*03*                     1.21           (1.01--1.46)   0.0366
  *DRB1\*14*:*05*                     1.18           (0.98--1.41)   0.0727
  *DRB1\*14*:*06*                     1.19           (0.99--1.42)   0.0625
  *DRB1\*14*:*07*                     1.18           (0.99--1.42)   0.0664
  *DRB1\*14*:*54*                     1.18           (0.98--1.41)   0.0733
  *DRB1\*15*:*01*                     1.21           (1.01--1.46)   0.0373
  *DRB1\*15*:*02*                     1.16           (0.96--1.39)   0.1171
  *DRB1\*16*:*02*                     1.19           (0.99--1.42)   0.0628
  SE                                  1.37           (1.13--1.66)   0.0016
  *DRB1*                              1.47           (1.19--1.81)   0.0003
  ----------------------------------- -------------- -------------- ---------------

RA: rheumatoid arthritis, ACPA: anti-citrullinated peptide antibody, ACPA(+)RA: ACPA positive RA, OR: odds ratio, CI: confidence interval, SE: Shared epitope. The association of *DPB1\*02*:*01* with ACPA(+) RA was analyzed by logistic regression analysis. The first row indicates the results from unconditioned analyses. The other rows indicate the results from analyses conditioned on shown *DRB1* alleles. *P*~adjusted~ and OR~adjusted~ were calculated by conditional logistic regression analysis under the additive model.

The two-locus analysis was conducted to identify the primary role of *DRB1\*04*:*05* and *DPB1\*02*:*01* for the susceptibility of ACPA(+)RA ([S2 Table](#pone.0204459.s003){ref-type="supplementary-material"}). The OR for *DPB1\*02*:*01* in ACPA(+)RA patients with *DRB1\*04*:*05* was 1.45 (*P* = 0.0688, [S2 Table](#pone.0204459.s003){ref-type="supplementary-material"}), while the OR for *DPB1\*02*:*01* in ACPA(+)RA patients without *DRB1\*04*:*05* was 1.26 (*P* = 0.0356, [S2 Table](#pone.0204459.s003){ref-type="supplementary-material"}). On the other hand, the OR for *DRB1\*04*:*05* in ACPA(+)RA patients with *DPB1\*02*:*01* was 4.21 (*P* = 3.71X10^-12^, [S2 Table](#pone.0204459.s003){ref-type="supplementary-material"}), and the OR for *DRB1\*04*:*05* in ACPA(+)RA patients without *DPB1\*02*:*01* was 3.33 (*P* = 7.58X10^-15^, [S2 Table](#pone.0204459.s003){ref-type="supplementary-material"}). These results suggested the independent roles of *DRB1\*04*:*05* and *DPB1\*02*:*01* on the susceptibility of ACPA(+)RA.

When haplotype frequencies were compared between ACPA(+)RA patients and controls, three haplotypes including *DRB1\*04*:*05* were associated with the susceptibility of ACPA(+)RA (*DRB1\*04*:*05-DPB1\*02*:*01*; Permutation *P*\<0.0001, *DRB1\*04*:*05-DPB1\*04*:*02*,; Permutation *P* = 0.0004, *DRB1\*04*:*05-DPB1\*05*:*01*; Permutation *P*\<0.0001, [S3 Table](#pone.0204459.s004){ref-type="supplementary-material"}), suggesting the primary role of *DRB1\*04*:*05*. On the other hand, some haplotypes including *DPB1\*02*:*01* were associated with the ACPA(+)RA susceptibility (*DRB1\*04*:*05-DPB1\*02*:*01*; Permutation *P* \<0.0001, *DRB1\*09*:*01-DPB1\*02*:*01*; Permutation *P* = 0.0048, [S3 Table](#pone.0204459.s004){ref-type="supplementary-material"}) or the protection (*DRB1\*04*:*06-DPB1\*02*:*01*; Permutation *P* = 0.0149, *DRB1\*08*:*02-DPB1\*02*:*01*; Permutation *P*\<0.0001, *DRB1\*13*:*02-DPB1\*02*:*01*; Permutation *P* = 0.0015, *DRB1\*15*:*01-DPB1\*02*:*01*; Permutation *P* = 0.0208, [S3 Table](#pone.0204459.s004){ref-type="supplementary-material"}), suggesting the influences of *DRB1* alleles on the effects of *DPB1\*02*:*01*. These data suggested the stronger effects of *DRB1* alleles on the ACPA(+)RA susceptibility or the protection.

Association of *DPB1* with ACPA(-)RA {#sec013}
------------------------------------

It was analyzed whether *DPB1* was also associated with ACPA(-)RA ([Table 4](#pone.0204459.t004){ref-type="table"}). In unconditioned analysis, no *DPB1* allele was associated with the susceptibility of ACPA(-)RA ([Table 4](#pone.0204459.t004){ref-type="table"}, left column). In order to elucidate whether each *DPB1* allele was independently associated with ACPA(-)RA, conditional logistic regression analysis was performed ([Table 4](#pone.0204459.t004){ref-type="table"}, right column). No association of *DPB1* alleles with the susceptibility of ACPA(-)RA was observed, when conditioned on *DRB1*. Association of *DPB1* was also analyzed with overall RA ([S4 Table](#pone.0204459.s005){ref-type="supplementary-material"}). In unconditioned analysis, no *DPB1* allele was associated with the overall RA ([S4 Table](#pone.0204459.s005){ref-type="supplementary-material"}, left column). When conditioned on *DRB1*, *DPB1\*02*:*01* was associated with the overall RA ([S4 Table](#pone.0204459.s005){ref-type="supplementary-material"}, right column). However, the association was weaker than ACPA(+)RA.

10.1371/journal.pone.0204459.t004

###### Conditional logistic regression analysis of *DPB1* alleles between ACPA(-)RA and controls.
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                    Uncoditioned   Conditioned on *DRB1*                                                                        
  ----------------- -------------- ----------------------- ------ --------------- -------- ---- ------ --------------- -------- ----
  *DPB1\*02*:*01*   118 (25.5)     198 (24.0)              1.09   (0.84--1.42)    0.5270   NS   1.20   (0.90--1.60)    0.2238   NS
  *DPB1\*02*:*02*   12 (2.6)       34 (4.1)                0.62   (0.32--1.21)    0.1645   NS   0.64   (0.31--1.33)    0.2277   NS
  *DPB1\*03*:*01*   21 (4.5)       36 (4.4)                1.05   (0.60--1.82)    0.8750   NS   0.86   (0.47--1.58)    0.6332   NS
  *DPB1\*04*:*01*   19 (4.1)       44 (5.3)                0.77   (0.45--1.32)    0.3456   NS   0.77   (0.36--1.64)    0.4931   NS
  *DPB1\*04*:*02*   42 (9.1)       69 (8.4)                1.10   (0.73--1.65)    0.6486   NS   0.88   (0.53--1.46)    0.6201   NS
  *DPB1\*05*:*01*   190 (41.1)     319 (38.6)              1.10   (0.88--1.39)    0.3891   NS   1.00   (0.77--1.30)    0.9834   NS
  *DPB1\*06*:*01*   3 (0.6)        3 (0.4)                 1.80   (0.36--8.98)    0.4746   NS   1.69   (0.31--9.30)    0.5491   NS
  *DPB1\*09*:*01*   36 (7.8)       87 (10.5)               0.72   (0.48--1.08)    0.1137   NS   0.88   (0.44--1.74)    0.7097   NS
  *DPB1\*13*:*01*   10 (2.2)       19 (2.3)                0.94   (0.43--2.05)    0.8734   NS   0.94   (0.41--2.15)    0.8856   NS
  *DPB1\*14*:*01*   6 (1.3)        8 (1.0)                 1.35   (0.46--3.94)    0.5829   NS   1.47   (0.44--4.98)    0.5326   NS
  *DPB1\*17*:*01*   1 (0.2)        3 (0.4)                 0.59   (0.06--5.75)    0.6530   NS   2.07   (0.09--47.37)   0.6493   NS
  *DPB1\*41*:*01*   3 (0.6)        2 (0.2)                 2.70   (0.45--16.30)   0.2778   NS   2.43   (0.37--15.87)   0.3554   NS

RA: rheumatoid arthritis, ACPA: anti-citrullinated peptide antibody, ACPA(-)RA: ACPA negative RA, OR: odds ratio, CI: confidence interval, *P*c: corrected *P* value, NS: not significant. Allele frequencies are shown in parenthesis (%). Association was tested between ACPA(-) RA and controls by logistic regression analysis. *P*~adjusted~ and OR~adjusted~ were calculated by conditional logistic regression analysis under the additive model. Corrected *P* (*P*c) values were calculated by multiplying the *P* value by the number of alleles tested.

Association of DPβ chain amino acid residues with ACPA(+)RA {#sec014}
-----------------------------------------------------------

Association of DRβ chain amino acid residues with ACPA(+)RA was confirmed ([S1 Fig](#pone.0204459.s001){ref-type="supplementary-material"}), as reported in the previous study \[[@pone.0204459.ref007]\]; 10Y, 11S, 12T, 13H, 33N, 70D, 96Y, and 98K in the DRβ chain showed associations. Two amino acid residues, 36A 55A, in the DPβ chain were slightly associated with ACPA(+)RA in unconditioned analysis ([Fig 1A](#pone.0204459.g001){ref-type="fig"}). In order to clarify whether each DPβ chain amino acid residue was independently associated with ACPA(+)RA, conditional logistic regression analysis was performed. Five amino acid residues, 84G (*P* = 3.20X10^-5^, *P*c = 0.0005, OR = 1.48, 95% CI 1.23--1.79), 85G (*P* = 3.20X10^-5^, *P*c = 0.0005, OR = 1.48, 95% CI 1.23--1.79), 86P (*P* = 3.20X10^-5^, *P*c = 0.0005, OR = 1.48, 95% CI 1.23--1.79), 87M (*P* = 3.20X10^-5^, *P*c = 0.0005, OR = 1.48, 95% CI 1.23--1.79), and 96R (*P* = 3.94X10^-5^, *P*c = 0.0006, OR = 1.48, 95% CI 1.23--1.78), in the DPβ chain were significantly associated with ACPA(+)RA, when conditioned on DRβ chain amino acid residues ([Fig 1B](#pone.0204459.g001){ref-type="fig"}). Since there are three haplotypes of these amino acid residues in the DPβ chain (84G-85G-86P-87M-96R, 84D-85E-86A-87V-96K, 84D-85E-86A-87V-96R), the results might reflect the effects of the haplotype of 84G-85G-86P-87M-96R on the susceptibility of ACPA(+)RA. The haplotype was actually associated with ACPA(+)RA in unconditioned analysis (*P* = 0.0078, OR = 1.24, 95% CI 1.06--1.44), or when conditioned on DRβ chain amino acid residues (*P*~adjusted~ = 4.11X10^-5^, OR~adjusted~ 1.47, 95%CI 1.22--1.77).

![Associations of amino acid residues in the DPβ chains with ACPA(+)RA.\
**(A)** Association was established between ACPA(+)RA and controls by logistic regression analysis. **(B)** Conditional logistic regression analysis was performed to clarify whether each DPβ chain amino acid residue was independently associated with ACPA(+)RA. *P*~adjusted~ values were calculated for amino acid residues in the DPβ chains, when conditioned on DRβ chain amino acid residues. Corrected *P* (*P*c) values were obtained by multiplying the *P* value by the number of amino acid residues tested. RA: rheumatoid arthritis, ACPA: anti-citrullinated peptide antibody, ACPA(+)RA: ACPA positive RA.](pone.0204459.g001){#pone.0204459.g001}

Discussion {#sec015}
==========

Although many investigations on the associations of *DRB1* alleles with the susceptibility of RA were performed, relatively fewer studies on the genetic effects of *DPB1* alleles for RA were conducted. There are a few direct reports on the independent association of *DPB1* alleles for the susceptibility of RA, though results of some studies suggested the role of *DPB1* alleles for RA \[[@pone.0204459.ref010],[@pone.0204459.ref013],[@pone.0204459.ref014],[@pone.0204459.ref016],[@pone.0204459.ref018]\]. *DPB1\*03*:*01* was associated with rheumatoid factor negative RA in European descent \[[@pone.0204459.ref010]\]. When arginine at position 71 of DRβ chain was possessed, *DPB1\*04*:*01* was associated with European RA \[[@pone.0204459.ref013]\]. *DPB1\*02*:*01* and *DPB1\*06*:*01* were associated with European RA without SE, whereas *DPB1\*04*:*01* was associated with European RA with SE \[[@pone.0204459.ref014]\]. *DPB1\*02*:*01* was associated with Japanese RA without *DRB1\*04*:*05* \[[@pone.0204459.ref016]\]. The association of *DPB1\*02*:*01* with the susceptibility of Japanese ACPA(+)RA and that of *DPB1\*04*:*01*and *DPB1\*09*:*01* with the protection were suggested \[[@pone.0204459.ref018]\]. However, the results of these previous studies could not conclude the independent association of *DPB1\*02*:*01* from *DRB1*. In the present study, we directly revealed it in Japanese populations.

It was reported that phenylalanine at position 9 in DPβ chain was reported to be independently associated with European ACPA(+)RA \[[@pone.0204459.ref021]\]. Glycine at position 84 in DPβ chain was also independently associated with Japanese ACPA(+)RA \[[@pone.0204459.ref023]\]. However, the independently associated *DPB1* alleles were not reported in these studies. In the present study, glycine at position 84 in DPβ chain was independently associated with ACPA(+)RA and 84G-85G-86P-87M-96R in DPβ chain was the ACPA(+)RA susceptible haplotype. This ACPA(+)RA associated haplotype was included in *DPB1\*02*:*01*, *DPB1\*02*:*02*, *DPB1\*04*:*01*, *DPB1\*04*:*02*, and *DPB1\*41*:*01*. Since the alleles other than *DPB1\*02*:*01* were not directly associated with ACPA(+)RA susceptibility ([Table 2](#pone.0204459.t002){ref-type="table"}, right column), *DPB1\*02*:*01* would be mainly contributed to the risk of ACPA(+)RA among them. The independent association of phenylalanine at position 9 in DPβ chain was not confirmed in the present study, though this amino acid residue was included in *DPB1\*02*:*01* and other alleles. This could be explained by the different distribution of *HLA* alleles in other ethnic populations. The amino acid residues 84, 85, 86, and 87 form the pocket 1 of DP peptide-binding groove \[[@pone.0204459.ref034]\]. This information suggested the involvement of peptides loaded on DP2 in the generation of ACPA or rheumatoid factor.

The association of *DPB1\*02*:*01* with ACPA(-)RA was not detected in the present study ([Table 4](#pone.0204459.t004){ref-type="table"}), because of the limited sample size of ACPA(-)RA. Although the association of *DPB1*with ACPA(-)RA was not found in the study on European populations \[[@pone.0204459.ref022]\], weak association was shown around *DP* loci in the other study on Japanese populations \[[@pone.0204459.ref023]\]. Therefore, this could be detected in future large scale studies. The independent association of *DPB1\*02*:*01* with ACPA(+)RA should be replicated in future studies in Japanese populations and should be also analyzed in other populations. It was the limitation of this study that the population stratification was not excluded \[[@pone.0204459.ref035],[@pone.0204459.ref036]\]. Thus, the present study revealed the independent association of *DPB1\*02*:*01* with ACPA(+)RA in Japanese populations.
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###### Associations of amino acid residues in the DRβ chains with ACPA(+)RA.

Association was established between ACPA(+)RA and controls by logistic regression analysis. Corrected P (Pc) values were obtained by multiplying the P value by the number of amino acid residues tested. RA: rheumatoid arthritis, ACPA: anti-citrullinated peptide antibody, ACPA(+)RA: ACPA positive RA.

(PDF)
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Click here for additional data file.

###### Logistic regression analysis of *DRB1* alleles in ACPA(+) RA and controls.

RA: rheumatoid arthritis, ACPA: anticitrullinated peptide antibody, ACPA(+)RA: ACPA positive RA, OR: odds ratio, CI: confidence interval, P c: corrected P value, NS: not significant. Allele frequencies are shown in parenthesis (%). Association was tested by logistic regression analysis.

(PDF)

###### 

Click here for additional data file.

###### Logistic regression analysis in the ACPA(+)RA patients and controls with or without *DRB1\*04*:*05* or *DPB1\*02*:*01*.

RA: rheumatoid arthritis, ACPA: anti-citrullinated peptide antibody, ACPA(+)RA: ACPA positive RA, OR: odds ratio, CI: confidence interval. Association was tested between the RA patients and the controls with or without *DRB1\*04*:*05* or *DPB1\*02*:*01* by logistic regression analysis.

(PDF)

###### 

Click here for additional data file.

###### *DRB1-DPB1* haplotype frequency in the ACPA(+)RA patients and controls.

RA: rheumatoid arthritis, ACPA: anti-citrullinated peptide antibody, ACPA(+)RA: ACPA positive RA. Haplotypes with more than 1% frequency in controls are shown.

(PDF)

###### 

Click here for additional data file.

###### Conditional logistic regression analysis of *HLA-DPB1* alleles in the RA patients and controls.

RA: rheumatoid arthritis, OR: odds ratio, CI: confidence interval. Association was tested between the RA patients and the controls by Logistic regression analysis.

(PDF)

###### 

Click here for additional data file.
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